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ABSTRACT Pyoderma gangrenosum is a rare, neutrophilic ulcerative 
skin disease of unknown etiology often associated with an underly-
ing systemic disease. We present a case of a pyoderma gangrenosum 
that was initially misdiagnosed and treated as squamous cell carcino-
ma in another hospital. Multiple surgical treatments triggered post-
operative exacerbations and further rapid progression of the lesions. 
History of pathergy, clinical findings, and histopathological features 
examined at our Department indicated pyoderma gangrenosum. 
The diagnosis was confirmed by excluding other diseases that could 
cause similar-appearing cutaneous lesions. No associated underlying 
disease was determined. After the diagnosis was confirmed, cortico-
steroid therapy was initiated until complete remission of ulcerations.
KEY WORDS: pyoderma gangrenosum; squamous cell carcinoma; 
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INTRODUCTION
Pyoderma gangrensum (PG) is an uncommon 
neutrophilic inflammatory skin disease that presents 
as rapidly spreading, sterile ulceration on the skin 
(1,2). The etiology is unknown, and the primary fac-
tors considered to contribute to the pathogenesis 
of PG are neutrophil dysfunction, genetic factors, 
and dysregulation of the immune system (3,4). It can 
appear spontaneously or as a result of pathergy af-
ter minor trauma or surgery (1). When triggered by 
pathergy it is easily mistaken for a postoperative in-
fection (3). Clinically and histologically PG is classi-
fied into four main types: ulcerative (classic), bullous 
(atypical), pustular, and vegetative (also known as 
superficial granulomatous pyoderma) (1,5). The most 
common presentation of pyoderma gangrenosum 
is an inflammatory papule, sterile pustule, or nodule 
that rapidly progresses to a painful ulcer with a vio-
laceous undermined border and a necrotic, purulent 
base (1,6). More than 50% of patients with PG devel-
op an associated systemic disease, most commonly 
inflammatory bowel disease, arthritis, or hematologic 
disorders (1,3,6,7). Clinical, histopathological and 
laboratory findings are nonspecific. The diagnosis is 
made based on the history of an underlying disease, 
typical clinical presentation, clinical history, and his-
topathological findings after excluding other ulcer-
ative cutaneous disorders (3). The differential diagno-
sis includes infectious disease, malignancy, vasculitis, 
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necrobiosis lipoidica, arterial or venous insufficiency, 
antiphospholipid-antibody syndrome, gangrenous 
thrombophlebitis, systemic lupus erythematosus, 
Behçet disease, Wegener’s granulomatosis, and poly-
arteritis nodosa (1,3,8). The first line of treatment in-
cludes systemic corticosteroids or immunosupressive 
drugs together with treatment of the associated sys-
temic disease (7,9,10).
CASE REPORT
A 76-year-old male patient with a 3-year history of 
two painful, extensive ulcers on the trunk was referred 
to our Department for evaluation and treatment of 
skin lesions. Initially presenting as inflammatory nod-
ules, the lesions were treated as chronic infection. 
Repeated surgical debridement procedures resulted 
in a rapid progression of necrotic, sterile ulcerations 
on the skin which were histopathologically verified as 
squamous cell carcinomas (SCC) in another hospital. 
Additionally, wide local excisions were made several 
times and were followed by rapid development of 
recurrence at the edges of the scars and further pro-
gression of ulcerations. 
On admission, clinical examination revealed two 
extensive, necrotic ulcerations with irregular, viola-
ceous, undermined borders; one on the back (Figure 
1, a) and the other one over the lower left abdomen 
(Figure 1, b). Other than fatigue and pain in the le-
sions, the patient did not complain of other systemic 
symptoms such as fever, malaise, arthralgia, or gas-
trointestinal symptoms.
Figure 1. Clinical findings in our patient at admission: two extensive, necrotic ulcerations with irregular, viola-
ceous, undermined borders; one presented on the back (a), the other over the lower left abdomen (b).
Figure 2. Extensive suppuration around a ruptured 
follicle with dense infiltrate of neutrophils (hematox-
ylin and eosin (H&E); ×40) (a). The conspicuous giant 
cells were noted along with neutrophils on the higher 
magnification (H&E; ×100) (b).
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Histopathological examination at our Depart-
ment showed perifollicular inflammation (Figure 2, 
a), pseudoepitheliomatous hyperplasia, dermal neu-
trophilic abscesses, palisading neutrophilic granulo-
mas, and epithelioid granulomas in superficial dermis 
(Figure 2, b) that indicated pyoderma gangrenosum. 
Laboratory findings revealed elevation of the eryth-
rocyte sedimentation rate (45 mm/h), elevation of 
C-reactive protein level (13.1 mg/L), elevated anti-
neutrophil cytoplasmic antibodies (c-ANCA) (1:40), 
and low levels of red blood cell count (3.97×1012/L), 
hemoglobin (114 g/L), hematocrit (0.341 L/L), and 
serum iron (7 µmol/L). C3 complement was slightly 
below normal (0.86 g/L). Microbiological culture was 
positive for Staphylococcus aureus. Therefore, cipro-
floxacin 500 mg twice daily was prescribed for two 
weeks, which resulted in mild improvement. Myco-
logical and mycobacterial cultures of intraopera-
tive samples were negative. Other laboratory tests, 
including a comprehensive metabolic panel, anti-
nuclear antibody titer, total hemolytic complement 
(CH50), C4 complement, immunofixation, Angioten-
sin-converting enzyme (ACE) inhibitors, circulating 
anti-cyclic citrullinated peptid antibodies, electro-
phoresis of proteins, immunoelectrophoresis, human 
immunodeficiency virus (HIV) test, venereal disease 
research laboratory (VDRL) test, Tteponema palli-
dum hemagglutination (TPHA) test, purified protein 
derivative (PPD) test, immune cell function test, and 
tumor markers were within normal ranges. Based on 
the above, the diagnosis of pyoderma gangrenosum 
was made. Additionally, the patient was evaluated 
for the presence of an associated underlying disease. 
Multi-slice computer tomography (MSCT) of the neck, 
chest, abdomen, and pelvis showed normal findings, 
and colonoscopy did not reveal an underlying inflam-
matory bowel disease. Interferon-gamma release as-
say (performed by using QuantiFERRON–TB®-Gold 
In tube test) was positive. Further tests, including a 
chest X-ray, spirometry, and arterial blood gas analy-
sis were normal. Results of three sequential sputum 
smears and culture testing were negative for acid-fast 
bacilli and Mycobacterium tuberculosis. 
After the diagnosis of PG was established with no 
associated underlying disease, therapy with 70 mg 
prednisone (1 mg/kg/d) orally was introduced. After 7 
days the dose was reduced by 5 mg every seven days 
to the dose of 5 mg which was continued for the next 
three months. Complete re- epithelialization of the 
lesions with cribriform scarring was achieved after 12 
weeks of corticosteroid therapy (Figure 3), followed 
by normalization of red blood cell count and serum 
iron level.
DISCUSSION
Pyoderma gangrenosum was first described by 
Brocq in 1916 as ‘phagédenisme géomeétrique’ (1,11). 
Believing that streptococcal infection was the main 
cause leading to secondary cutaneous gangrene, 
Figure 3. After 12 weeks of corticosteroid therapy: complete re-epithelialization of the lesions with cribriform 
scarring.
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it was named pyoderma gangrenosum in 1930 by 
Brunsting, Goeckerman, and O’Leary (1,12). Today, we 
know that despite its name it is neither an infectious 
nor a gangrenous disease and its etiology is still un-
known. The diagnosis is made by exclusion of other 
similar cutaneous lesions.
Since there are no pathognomonic clinical, his-
tological, or laboratory findings, some authors have 
proposed diagnostic criteria for ulcerative PG (7,13). 
Two major criteria of which both need to be fulfilled 
are rapid progression of a painful, necrotic ulceration 
with an irregular, violaceous, and undermined border 
along with exclusion of other causes of cutaneous 
ulcerations. Four minor criteria of which at least two 
have to be fulfilled are a patient history suggestive 
of patergy or clinical presence of cribriform scarring, 
presence of a systemic disease associated with PG, 
histopathological findings, and rapid response to sys-
temic corticosteroid treatment.
In our patient, after excluding other dermatoses 
that might present with similar clinical findings and 
based on pathohistological elements, rapid progres-
sion of extensive ulcerations, typical clinical presenta-
tion, and history of pathergy, the diagnosis of pyoder-
ma gangrenosum was established. Positive bacterial 
culture for Staphylococcus aureus was highly sugges-
tive of secondary infection since cultures from early 
lesions were sterile. Histopathology demonstrated 
necrosis of the superficial dermis and epidermis with 
an underlying mixed inflammatory cell infiltrate and 
abscess formation, which are typical elements in the 
histopathology of ulcerative PG (14). The primary ob-
jective in obtaining a biopsy specimen is to exclude 
other causes of ulcerations such as infection, malig-
nancy, or vasculitis (1,13). In our case, the exclusion 
of a malignant disease was the most important as-
pect of the differential diagnosis. Although the clini-
cal findings were partially suggestive of squamous 
cell carcinoma, multiple biopsies did not reveal any 
evidence of malignancy. Pseudoepitheliomatous hy-
perplasia that was detected could have had imitated 
squamous cell carcinoma at an early stage in the dis-
ease evolution and led to histological misdiagnosis 
of SCC (15). Being characterized by pathergy, exacer-
bations and further progression of ulcerations which 
were triggered by multiple surgeries were mistaken 
for a relapse of SCC. As with histopathology, there 
are no pathognomonic laboratory findings that pro-
vide definitive diagnosis of PG. Nonspecific findings 
such as leukocytosis, elevation of the erythrocyte 
sedimentation rate, and elevation of C-reactive pro-
tein levels may be present (16). Laboratory tests are 
most useful for excluding the differential diagnosis 
and identifying the presence of the diseases associ-
ated with PG. In our case, high erythrocyte sedimen-
tation rate and low levels of red blood cell count were 
a result of an inflammatory response to a chronic 
disease. Elevation of c-ANCA titer does not necessar-
ily indicate Wegener’s granulomatosis. According to 
Weedon, positive c-ANCA and vascular changes sug-
gestive for lymphocytic or leukocytoclastic vasculitis 
in histopathology do not exclude the diagnosis of PG 
as previously thought (14). Vasculitis in PG is a sec-
ondary event resulting from the deposition of C3, im-
munoglobulin M (IgM), and fibrin in blood vessels (3). 
Pulmonary assessment did not confirm active or la-
tent pulmonary tuberculosis. In our case, the positive 
QuantiFERON test was a result of immune response 
to the past infection with Mycobacterium tuberculo-
sis. It is important to consider tuberculosis as a pos-
sible infectious disease associated with PG, especially 
when the decision on treatment for pyoderma gan-
grenosum with immunosuppressive drugs must be 
made, since tuberculosis can be reactivated after in-
tense immunosuppressive therapy (17).
There is no golden standard for treatment of pyo-
derma gangrenosum (10). The first line of treatment 
includes systemic corticosteroids (prednisone 0.5-1 
mg/kg/d) or cyclosporine (4-5 mg/kg/d), together 
with treatment of the associated systemic disease 
(9,18). The rapid response to prednisone and clinical 
finding of cribriform scarring confirmed the diagno-
sis in our patient. 
In our case, all the criteria for diagnosing pyoder-
ma gangrenosum were met except for the presence 
of underlying diseases of which inflammatory bowel 
disease, arthropathies, and hematologic disease or 
hematologic malignancy are the most common (7). 
It is important to identify PG-associated comorbidi-
ties since successful treatment of them may lead to 
improvement or complete remission of pyoderma 
gangrenosum.
CONCLUSION
Pyoderma gangrenosum is commonly misdiag-
nosed and treated surgically, which can lead to de-
velopment of a rapidly spreading ulceration due to 
pathergy. In our case, awareness of the possible his-
tological misdiagnosis of SCC at an early stage of the 
disease could have prevented unnecessary surgical 
procedures. If there is further progression instead of 
improvement of the skin lesion after surgical treat-
ments, the diagnosis of pyoderma gangrenosum 
should be considered, and such patients should be 
evaluated for the presence of associated systemic dis-
eases.
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